Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jinyu Bio-Technology CoSHSE:600201 -3.66%64 PS Ratio is 9.61 as of Jul. 19, 2026, which is 9% below its 10-year median of 10.57. GuruFocus rates SHSE:600201 with a GF Score™ of 64/100 and a GF Value™ of ¥8.33 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 931 Biotechnology companies, Jinyu Bio-Technology Co ranks worse than 50.81% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Jinyu Bio-Technology Co's share price is ¥11.58.
Jinyu Bio-Technology Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1.21. Hence, Jinyu Bio-Technology Co's PS Ratio for today is 9.61.
The historical rank and industry rank for Jinyu Bio-Technology Co's PS Ratio or its related term are showing as below:
SHSE:600201'
s PS Ratio Range Over the Past 10 Years
Min: 4.05 Med: 10.57 Max: 27.09
Current: 9.61
During the past 13 years, Jinyu Bio-Technology Co's highest PS Ratio was 27.09. The lowest was 4.05. And the median was 10.57.
SHSE:600201's PS Ratio is ranked worse than 50.81% of 931
companies
in the Biotechnology industry
Industry Median: 9.32
vs SHSE:600201: 9.61
Jinyu Bio-Technology Co Ltd revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Jinyu Bio-Technology Co was 3.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -3.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -0.90% per year.
During the past 13 years, Jinyu Bio-Technology Co's highest 3-Year average Revenue per Share Growth Rate was 31.10% per year. The lowest was -11.40% per year. And the median was 10.60% per year.
Back to Basics: PS Ratio
Jinyu Bio-Technology Co (SHSE:600201) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600201 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Jinyu Bio-Technology Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jinyu Bio-Technology Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Jinyu Bio-Technology Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Jinyu Bio-Technology Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Jinyu Bio-Technology Co's Share Price of today is ¥11.58. Jinyu Bio-Technology Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.21.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Jinyu Bio-Technology Co (SHSE:600201) has a PS Ratio of 9.61 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Jinyu Bio-Technology Co and its competitors. This is near median its historical median of 10.57. Over the past decade, Jinyu Bio-Technology Co's PS Ratio has ranged from 4.05 to 27.09. According to the industry distribution chart, Jinyu Bio-Technology Co ranks #473 out of 931 companies in the Biotechnology industry, placing it in the top 50.8%.
Is Jinyu Bio-Technology Co's PS Ratio too high?
Jinyu Bio-Technology Co's current PS Ratio of 9.61 is near median its 10-year median of 10.57. Over the past 10 years, this metric has ranged from a low of 4.05 to a high of 27.09. The Biotechnology industry median PS Ratio is 9.32. Jinyu Bio-Technology Co's value of 9.61 is 3.1% above this industry median. Based on the distribution chart, Jinyu Bio-Technology Co ranks #473 out of 931 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Jinyu Bio-Technology Co has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jinyu Bio-Technology Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jinyu Bio-Technology Co ranks #473 out of 931 companies for PS Ratio. This places Jinyu Bio-Technology Co in the lower half of its industry. The industry median PS Ratio is 9.32. Jinyu Bio-Technology Co's value of 9.61 is 3.1% above this benchmark. Historically, Jinyu Bio-Technology Co's own PS Ratio has ranged from 4.05 to 27.09 over the past decade. While the company's 10-year median is 10.57 vs. the industry median of 9.32, Jinyu Bio-Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.32, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jinyu Bio-Technology Co's current PS Ratio of 9.61 is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Jinyu Bio-Technology Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jinyu Bio-Technology Co's current PS Ratio is 9.61, which is near median its own 10-year median of 10.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jinyu Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co (SHSE:600201) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.33, compared to a current price of ¥11.58 — trading 39% above its estimated fair value. The current PS Ratio is 9.61, which is near median its 10-year median of 10.57 and 3.1% above the Biotechnology industry median of 9.32. Jinyu Bio-Technology Co's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Jinyu Bio-Technology Co (SHSE:600201), the current PS Ratio is 9.61 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jinyu Bio-Technology Co (SHSE:600201) Overvalued in 2026?
Based on GuruFocus' analysis, Jinyu Bio-Technology Co stock appears to be overvalued.
The current stock price of ¥11.58 is trading 39% above its estimated GF Value™ of ¥8.33.
GuruFocus considers Jinyu Bio-Technology Co to be Significantly Overvalued.
Key valuation signals for SHSE:600201:
PS Ratio: 9.61 (near median its 10-year median of 10.57)
GF Value™: ¥8.33 vs. price of ¥11.58 (39% above fair value)
Industry Position: 3.1% above the Biotechnology median (#473 of 931)
No single metric tells the full story. See the SHSE:600201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jinyu Bio-Technology Co Ltd is engaged in the development and sales of veterinary biological products. Its products are used for pigs, poultry, pets, and ruminants.
64GF Score
Get the complete analysis for SHSE:600201
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600201 has been successfully added to your 
